BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 30918073)

  • 1. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
    Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential requirement for CD80 and CD80/CD86-dependent costimulation in the lung immune response to an influenza virus infection.
    Lumsden JM; Roberts JM; Harris NL; Peach RJ; Ronchese F
    J Immunol; 2000 Jan; 164(1):79-85. PubMed ID: 10604996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
    Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
    Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.
    Caux C; Vanbervliet B; Massacrier C; Azuma M; Okumura K; Lanier LL; Banchereau J
    J Exp Med; 1994 Nov; 180(5):1841-7. PubMed ID: 7525840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.
    Fargeas CA; Truneh A; Reddy M; Hurle M; Sweet R; Sékaly RP
    J Exp Med; 1995 Sep; 182(3):667-75. PubMed ID: 7544393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions.
    Greene JL; Leytze GM; Emswiler J; Peach R; Bajorath J; Cosand W; Linsley PS
    J Biol Chem; 1996 Oct; 271(43):26762-71. PubMed ID: 8900156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
    Guo Y; Wu Y; Zhao M; Kong XP; Liu Y
    J Exp Med; 1995 Apr; 181(4):1345-55. PubMed ID: 7535334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
    Lane P
    Ann N Y Acad Sci; 1997 Apr; 815():392-400. PubMed ID: 9186685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
    Linsley PS; Greene JL; Brady W; Bajorath J; Ledbetter JA; Peach R
    Immunity; 1994 Dec; 1(9):793-801. PubMed ID: 7534620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cowpox virus encodes a protein that binds B7.1 and B7.2 and subverts T cell costimulation.
    Wang X; Piersma SJ; Elliott JI; Errico JM; Gainey MD; Yang L; Nelson CA; Yokoyama WM; Fremont DH
    Proc Natl Acad Sci U S A; 2019 Oct; 116(42):21113-21119. PubMed ID: 31575740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.
    Zheng P; Wu Y; Guo Y; Lee C; Liu Y
    Proc Natl Acad Sci U S A; 1998 May; 95(11):6284-9. PubMed ID: 9600957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo.
    Bai XF; Liu J; May KF; Guo Y; Zheng P; Liu Y
    Blood; 2002 Apr; 99(8):2880-9. PubMed ID: 11929778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of memory CD8+ T cell differentiation by CD80/CD86-CD28 costimulation and restoration by IL-2 during the recall response.
    Fuse S; Zhang W; Usherwood EJ
    J Immunol; 2008 Jan; 180(2):1148-57. PubMed ID: 18178855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTLA4 depletes T cell endogenous and trogocytosed B7 ligands via cis-endocytosis.
    Xu X; Dennett P; Zhang J; Sherrard A; Zhao Y; Masubuchi T; Bui JD; Chen X; Hui E
    J Exp Med; 2023 Jul; 220(7):. PubMed ID: 37042938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of murine Lyme borreliosis by interruption of the B7/CD28 T-cell costimulatory pathway.
    Shanafelt MC; Kang I; Barthold SW; Bockenstedt LK
    Infect Immun; 1998 Jan; 66(1):266-71. PubMed ID: 9423867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD80 and CD86 are not equivalent in their ability to induce the tyrosine phosphorylation of CD28.
    Slavik JM; Hutchcroft JE; Bierer BE
    J Biol Chem; 1999 Jan; 274(5):3116-24. PubMed ID: 9915850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the costimulatory requirements for generating human virus-specific in vitro T helper and effector responses.
    Blazevic V; Trubey CM; Shearer GM
    J Clin Immunol; 2001 Jul; 21(4):293-302. PubMed ID: 11506200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking CD40 - CD154 and CD80/CD86 - CD28 interactions during primary allogeneic stimulation results in T cell anergy and high IL-10 production.
    Van Gool SW; Vermeiren J; Rafiq K; Lorr K; de Boer M; Ceuppens JL
    Eur J Immunol; 1999 Aug; 29(8):2367-75. PubMed ID: 10458748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.